Trial Profile
An Open-Label, Multicenter, Phase 2 Study of Single-Agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects With Metastatic Castrate-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Carlumab (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Janssen Biotech
- 10 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2011 Planned End Date changed from 1 Nov 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 30 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.